Alto Neuroscience to Participate in Upcoming Investor Conferences
26 February 2025 - 12:03AM
Business Wire
Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage
biopharmaceutical company focused on the development of novel
precision medicines for neuropsychiatric disorders, today announced
that members of the Company management team will present at the
following upcoming investor conferences and events in March:
- TD Cowen 45th Annual Health Care Conference, March 3-5th
2025:
- Format: Presentation and one-on-one investor meetings
- Presentation Date/Time: Tuesday, March 4, 2025, at 9:50 am
ET
- Location: Marriott Copley Place, Boston, MA
- Leerink’s Global Healthcare Conference 2025, March 10-12th
2025:
- Format: Presentation and one-on-one investor meetings
- Presentation Date/Time: Wednesday, March 12, 2025, at 8:00 am
ET
- Location: W South Beach, Miami, FL
- Stifel 2025 Virtual CNS Forum, March 18-19th 2025:
- Format: Presentation and one-on-one investor meetings
- Presentation Date/Time: Tuesday, March 18, 2025, at 1:00 pm
ET
Available presentations will be accessible via a live webcast on
the Events and Presentations page in the Investors section of
Alto’s website and a replay will be available following the
presentation.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company
with a mission to redefine psychiatry by leveraging neurobiology to
develop personalized and highly effective treatment options. Alto’s
Precision Psychiatry Platform™ measures brain biomarkers by
analyzing EEG activity, neurocognitive assessments, wearable data,
and other factors to better identify which patients are more likely
to respond to Alto product candidates. Alto’s clinical-stage
pipeline includes novel drug candidates in depression,
schizophrenia, and other mental health conditions. For more
information, visit www.altoneuroscience.com or follow Alto on
X.
Availability of Information on Alto’s Website
Alto routinely uses its investor relations website to post
presentations to investors and other important information,
including information that may be material. Accordingly, Alto
encourages investors and others interested in Alto to review the
information it makes public on its investor relations website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250225919531/en/
Investor Contact: Nick Smith
investors@altoneuroscience.com
Media Contact: Mari Purpura
media@altoneuroscience.com
Alto Neuroscience (NYSE:ANRO)
Historical Stock Chart
From Feb 2025 to Mar 2025
Alto Neuroscience (NYSE:ANRO)
Historical Stock Chart
From Mar 2024 to Mar 2025